Le Lézard
Classified in: Health
Subjects: NPT, FDA, AVO, MAT

Power to Decide Statement on Over-the-Counter Birth Control Release and Pricing


First ever FDA-approved over-the-counter birth control, Opill, set to hit store shelves soon.

WASHINGTON, March 4, 2024 /PRNewswire-PRWeb/ -- Today, the pharmaceutical company Perrigo announced that it will begin shipping the first ever FDA-approved over-the-counter (OTC) daily oral contraceptive pill, Opill, to retailers across the country. This marks a historic advancement in access to contraception, which for decades advocates have been fighting for.

"At a time when reproductive health and rights are under attack, it is critical that everyone has the ability to access a birth control pill without barriers such as cost, prescriptions, insurance coverage and medical appointments," said Power to Decide, CEO, Dr. Raegan McDonald-Mosley, MD, MPH.

Additionally, Perrigo recommended a retail price of $19.99 for a one-month supply of Opill, and $49.99 for a three-month supply. However, it will be up to individual retailers to set their price, which may vary across stores and locations. Consumers can expect to find Opill in retailers and pharmacies in the coming weeks.

While the OTC birth control pill will greatly increase contraceptive access, the price will continue to be a barrier for many. There is still a need for insurance coverage of all OTC contraception without a prescription, a robust consumer assistance program from Perrigo, and availability of the full range of contraceptive methods - including Opill - at safety net clinics to ensure equitable access of contraception for all.

In response to Perrigo's announcement, Power to Decide CEO, Dr. Raegan McDonald-Mosley, MD, MPH, issued the following statement:

"FDA approval of the first over-the-counter birth control pill is a major milestone in reproductive health and a critical step toward ensuring contraceptive access for all, but we need to make sure that those in need can actually afford to use it. When it comes to contraception, affordability is critical to meaningful access.

"As a practicing OBGYN, I know that most patients do not need to visit their health care provider to safely and effectively use birth control pills, and that the requirement for a visit presents significant obstacles for many people. Ensuring that over-the-counter birth control is affordable, covered by insurance and accessible for all ages will especially help those in contraceptive deserts?counties where people in need of publicly funded contraceptive care lack reasonable access to a clinic that provides the full range of contraceptive methods.

"At a time when reproductive health and rights are under attack, it is critical that everyone has the ability to access a birth control pill without barriers such as cost, prescriptions, insurance coverage and medical appointments. Heading to your local convenience or retail store for OTC birth control and not having to wait weeks or even months for a medical appointment is a game changer. At Power to Decide, we will continue to push for everyone to have equitable access to take control of their reproductive and sexual health care."

To explore all your birth control options and learn more about Opill, visit Bedsider.org.

Power to Decide is a nonprofit, nonpartisan organization that works to advance sexual and reproductive well-being for all by providing trusted information, expanding access to quality services, and catalyzing culture change.

Bedsider, a program of Power to Decide, is an evidence-based digital platform that offers medically-accurate, relevant, and resonate information on all aspects of reproductive well-being, including sex, sexual health, and birth control. Find a birth control method that works for you at Bedsider.org.

Media Contact

Jacqueline Pelella, Power to Decide, 202-478-8534, [email protected], https://powertodecide.org/

SOURCE Power to Decide


These press releases may also interest you

at 07:30
Quipt Home Medical Corp. (the "Company") ?, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, announced today that the Toronto Stock Exchange ("TSX") has accepted the Company's notice of intention to implement a...

at 07:30
Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will present long-term efficacy, safety and...

at 07:30
MedBright AI Investments Inc. (the "Company" or "MedBright") today announced MedMatrix, a product in which it has a significant investment, has launched two new demonstration videos highlighting the capabilities of the MedMatrix AI Reporter and...

at 07:30
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally...

at 07:30
VitalHub Corp. (the "Company" or "VitalHub") is pleased to announce that it will release its financial results for its first quarter 2024 ended March 30th, 2024, after market close on May 9th, 2024. The Company will subsequently hold a conference...

at 07:25
Arbutus Biopharma Corporation ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today...



News published on and distributed by: